Abstract
Lactic acid bacteria (LAB) represent a heterogeneous group of microorganisms that have been shown to possess therapeutic properties since they are able to prevent the development of some diseases, as shown mostly on animal models for cancer, infections and gastrointestinal disorders such as intestinal inflammation. LAB have been shown to regulate mucosal immune responses by modulating the production and liberation of regulatory agents such as cytokines by the host. Some of these cytokines, such as the anti-inflammatory interleukin-10 (IL-10), modulate the inflammatory immune response, thus immunomodulation is a mechanism by which LAB can prevent certain inflammatory bowel diseases (IBD). Since oxidative stress participates in the inflammatory processes and in the appearance of damages in pathologies of the gastrointestinal tract of humans such as IBD, LAB could also prevent inflammation by eliminating reactive oxygen species (ROS) through the activity of antioxidant enzymes. In order to obtain novel strains or enhance beneficial effects of LAB, genetic engineering has been used to produce either antioxidant enzymes (such as catalases and superoxide dismutases) or anti-inflammatory cytokines (such as IL-10) producing LAB. These novel strains have successfully been used to prevent inflammatory bowel diseases in animal models and could be evaluated in human clinical trials. Here, we present an overview of the current knowledge of the mechanisms by which LAB can be used to prevent undesired intestinal inflammatory responses and could be used as a therapeutic tool for IBD.
Keywords: Anti-inflammatory, antioxidant, catalase, immune regulation, interleukin-10, lactic acid bacteria, superoxide dismutase.
Anti-Infective Agents
Title:Mechanisms Involved in the Anti-Inflammatory Properties of Native and Genetically Engineered Lactic Acid Bacteria
Volume: 11 Issue: 1
Author(s): Jean G. LeBlanc, Silvina del Carmen, Meritxell Z. Turk, Fernanda A. Lima, Daniela S. Pontes, Anderson Miyoshi, Vasco Azevedo and Alejandra de Moreno de LeBlanc
Affiliation:
Keywords: Anti-inflammatory, antioxidant, catalase, immune regulation, interleukin-10, lactic acid bacteria, superoxide dismutase.
Abstract: Lactic acid bacteria (LAB) represent a heterogeneous group of microorganisms that have been shown to possess therapeutic properties since they are able to prevent the development of some diseases, as shown mostly on animal models for cancer, infections and gastrointestinal disorders such as intestinal inflammation. LAB have been shown to regulate mucosal immune responses by modulating the production and liberation of regulatory agents such as cytokines by the host. Some of these cytokines, such as the anti-inflammatory interleukin-10 (IL-10), modulate the inflammatory immune response, thus immunomodulation is a mechanism by which LAB can prevent certain inflammatory bowel diseases (IBD). Since oxidative stress participates in the inflammatory processes and in the appearance of damages in pathologies of the gastrointestinal tract of humans such as IBD, LAB could also prevent inflammation by eliminating reactive oxygen species (ROS) through the activity of antioxidant enzymes. In order to obtain novel strains or enhance beneficial effects of LAB, genetic engineering has been used to produce either antioxidant enzymes (such as catalases and superoxide dismutases) or anti-inflammatory cytokines (such as IL-10) producing LAB. These novel strains have successfully been used to prevent inflammatory bowel diseases in animal models and could be evaluated in human clinical trials. Here, we present an overview of the current knowledge of the mechanisms by which LAB can be used to prevent undesired intestinal inflammatory responses and could be used as a therapeutic tool for IBD.
Export Options
About this article
Cite this article as:
G. LeBlanc Jean, del Carmen Silvina, Z. Turk Meritxell, A. Lima Fernanda, S. Pontes Daniela, Miyoshi Anderson, Azevedo Vasco and de Moreno de LeBlanc Alejandra, Mechanisms Involved in the Anti-Inflammatory Properties of Native and Genetically Engineered Lactic Acid Bacteria, Anti-Infective Agents 2013; 11 (1) . https://dx.doi.org/10.2174/22113626130107
DOI https://dx.doi.org/10.2174/22113626130107 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
Call for Papers in Thematic Issues
An Overview of Drugs for Multiple Targets and Variants of SARS-CoV-2 Through Artificial Intelligence, Machine Learning, Deep Learning, and Experimental Analysis
The emergence and rapid evolution of SARS-CoV-2 variants have posed significant challenges in the ongoing fight against the COVID-19 pandemic. The development of effective treatments for multiple viral targets and variants demands innovative approaches, including artificial intelligence (AI), machine learning (ML), and deep learning (DL) techniques. This special issue aims ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders
Current Genomics Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma
Mini-Reviews in Medicinal Chemistry Synthesis and Preliminary Evaluation of 5-[18F]fluoroleucine
Current Radiopharmaceuticals Estrogen, Immunity & Autoimmune Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Biosynthetic and Metabolic Alterations in Cancer Growth
Current Angiogenesis (Discontinued) The Gut Microbiota as a Target for Improved Surgical Outcome and Improved Patient Care
Current Pharmaceutical Design Lanthionine Synthetase Component C-Like Protein 2: A New Drug Target for Inflammatory Diseases and Diabetes
Current Drug Targets Synthesis and Anticancer Activity of 2,4,5-triaryl Imidazole Derivatives
Letters in Drug Design & Discovery Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine The Membrane-targeted Alkylphosphocholine Erufosine Interferes with Survival Signals from the Extracellular Matrix
Anti-Cancer Agents in Medicinal Chemistry Colorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics
Current Pharmaceutical Design Fecal Microbiota Transplant: Latest Addition to Arsenal against Recurrent <i>Clostridium difficile</i> Infection
Recent Advances in Anti-Infective Drug Discovery Investigation of Novel Chemical Inhibitors of Human Lysosomal Acid Lipase: Virtual Screening and Molecular Docking Studies
Combinatorial Chemistry & High Throughput Screening Subject Index to Volume 4
Current Topics in Medicinal Chemistry Regulation of Runx2 and Its Signaling Pathways by MicroRNAs in Breast Cancer Metastasis
Current Protein & Peptide Science Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design Potential Molecular Targets of Ampelopsin in Prevention and Treatment of Cancers
Anti-Cancer Agents in Medicinal Chemistry Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins
Current Gene Therapy Optimising the Azeotropic Drying of 18F-Fluorine Wayto Improve the 18F-Fluorocholine Radiochemical Yield
Current Radiopharmaceuticals